Design Novel Parp Inhibitor Biomarkers That Are More Specific And Tumor-SelectivPosted by Sachin B on May 21st, 2021 Poly (ADP-ribose) polymerase or PARP inhibitor biomarkers play a major role in the treatment and management of various chronic diseases. It is very important to design novel PARP inhibitors that are more specific and tumor-selective. Biomarkers can be used to determine if a patient is improving.
PARP inhibitor biomarkers play a major role in the treatment and management of cancer. Researchers have found that increasing the activity of an enzyme called caspase causes the prostate-specific antigen (PSA) to become more sensitive to negative stimuli, which means that it will be more responsive to chemotherapy. These findings were reported at the annual meeting of the American Association for Cancer Research. This means that researchers can use the PSA test to find people who are most at risk of developing cancer. Using prostate-specific antigen tests early in the disease can save the life of a person with aggressive cancer.
It is important to develop better mechanistic-based strategies using reliable predictive biomarkers for PARP inhibitor monotherapy as well as combination treatments and identify situations that can re-sensitize recalcitrant tumor cells to PARP activity inhibition or modulation to treat cancer patients more safely and efficiently. There are several different inhibitors that are used in the PARP inhibitor biomarkers. Most of these chemicals act by binding with the receptor sites on cancer cells.
They stop the ability of the receptors to interact with DNA. Some of these specific inhibitors stop the DNA binding on the receptors and cause the receptors to not be inhibited. This allows the cancer drugs to continue to do their work without having to worry about damaging the cancerous cells. The effect of these specific inhibitors on cancer cells has not been studied very much. However, many of the inhibitors bind at multiple sites. When more than one drug is tested in this type of test, it is more likely that the results will be consistent and will be reliable in helping to treat people with advanced cancers.
Like it? Share it! More by this author |